-The Telegraph New Delhi: A public health expert has questioned the Indian government's commitment to effectively tackling tuberculosis, citing slashed funds, late diagnoses and a failure to curb incorrect or inappropriate prescriptions by many private practitioners. India's plans to eliminate TB as a public health problem by 2050 will remain unachievable without sustained financial support, strong political will and stringent regulation, Mahavir Golechha has said. Golechha is a faculty member with the health...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...

-The Guardian Universal healthcare is often presented as an idealistic goal that remains out of reach for all but the richest nations. That's not the case, writes Amartya Sen. Look at what has been achieved in Rwanda, Thailand and Bangladesh Twenty-five hundred years ago, the young Gautama Buddha left his princely home, in the foothills of the Himalayas, in a state of agitation and agony. What was he so distressed about?...

In the midst of national debates over the need for labour laws reforms and the efficacy of MG-NREGA in checking distress migration, a new report brings spotlight on the miserable living and working conditions of unorganized migrant workers from Rajasthan. Titled Their Own Country: A Profile of Labor Migration from Rajasthan, the report prepared jointly by Aajeevika Bureau and UNESCO informs us that 70% of seasonal migrant workers from Rajasthan...

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...